[go: up one dir, main page]

DK0772624T3 - Interleukin-15 - Google Patents

Interleukin-15

Info

Publication number
DK0772624T3
DK0772624T3 DK94915781T DK94915781T DK0772624T3 DK 0772624 T3 DK0772624 T3 DK 0772624T3 DK 94915781 T DK94915781 T DK 94915781T DK 94915781 T DK94915781 T DK 94915781T DK 0772624 T3 DK0772624 T3 DK 0772624T3
Authority
DK
Denmark
Prior art keywords
polypeptides
derivatives
interleukin
mammalian
etf
Prior art date
Application number
DK94915781T
Other languages
English (en)
Inventor
Kenneth H Grabstein
Dirk M Anderson
June R Eisenman
Charles Rauch
Victor Fung
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Priority claimed from ZA942636A external-priority patent/ZA942636B/xx
Application granted granted Critical
Publication of DK0772624T3 publication Critical patent/DK0772624T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK94915781T 1994-04-06 1994-04-06 Interleukin-15 DK0772624T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US1994/003793 WO1995027722A1 (en) 1994-04-06 1994-04-06 Interleukin-15
NZ266264A NZ266264A (en) 1994-04-06 1994-04-06 Mammalian epithelium-derived t-cell factor called interleukin-15
ZA942636A ZA942636B (en) 1994-04-06 1994-04-18 Interleukin-15
OA60897A OA10375A (en) 1994-04-06 1996-09-27 Interleukin-15

Publications (1)

Publication Number Publication Date
DK0772624T3 true DK0772624T3 (da) 2000-11-13

Family

ID=33314371

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94915781T DK0772624T3 (da) 1994-04-06 1994-04-06 Interleukin-15

Country Status (11)

Country Link
EP (1) EP0772624B1 (da)
AT (1) ATE196315T1 (da)
CA (1) CA2186747C (da)
DE (1) DE69425906T2 (da)
DK (1) DK0772624T3 (da)
ES (1) ES2151927T3 (da)
GR (1) GR3035019T3 (da)
NZ (1) NZ266264A (da)
OA (1) OA10375A (da)
PT (1) PT772624E (da)
WO (1) WO1995027722A1 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69622854T2 (de) * 1995-04-02 2003-04-10 Chugai Seiyaku K.K., Tokio/Tokyo Arzneimittel zur Heilung von Thrombozytopenie
JP4128625B2 (ja) 1995-10-17 2008-07-30 ウェイン ステイト ユニヴァーシティ チキンインターロイキン−１５及びその使用
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
EP1627918A1 (en) * 1996-04-26 2006-02-22 Beth Israel Deaconess Medical Center, Inc. Antagonists of interleukin-15
US6451308B1 (en) 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
EP0927254B1 (en) * 1996-04-26 2005-06-22 Beth Israel Deaconess Medical Center, Inc. Antagonists of interleukin-15
US6087172A (en) * 1997-10-31 2000-07-11 Hisamitsu Pharmaceutical Co., Inc. Ribozymes targeted to human IL-15 mRNA
US5985663A (en) * 1998-11-25 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of interleukin-15 expression
WO2000050569A1 (en) * 1999-02-24 2000-08-31 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
US6828147B1 (en) 1999-02-24 2004-12-07 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
JP2003533488A (ja) 2000-05-12 2003-11-11 ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド 免疫抑制を達成するための組成物および方法
CU23093A1 (es) * 2002-10-09 2005-10-19 Ct Ingenieria Genetica Biotech Composición vacunal que comprende interleucina-15 (il-15)
CN100427597C (zh) * 2003-11-26 2008-10-22 中国医学科学院基础医学研究所 可用于生产人重组白细胞介素-15的原核表达工程菌及纯化方法
CU23472A1 (es) 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
PT1809321E (pt) * 2004-10-08 2012-05-17 Us Gov Health & Human Serv Imunoterapia adotiva com sobrevivência aumentada de linfócitos
US8124084B2 (en) 2005-05-17 2012-02-28 University Of Connecticut Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US9303080B2 (en) 2006-01-13 2016-04-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
ES2518393T3 (es) 2007-05-11 2014-11-05 Altor Bioscience Corporation Moléculas de fusión y variantes de IL-15
NZ703668A (en) 2007-06-27 2016-07-29 Us Sec Dep Of Health And Human Services Complexes of il-15 and il-15ralpha and uses thereof
WO2009135031A1 (en) 2008-04-30 2009-11-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Substituted il-15
CA2768965C (en) 2009-08-14 2019-06-04 George N. Pavlakis Use of il-15 to increase thymic output and to treat lymphopenia
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
DK3327040T3 (da) 2010-09-21 2021-09-20 Altor Bioscience Corp Multimeriske opløselige il-15-fusionsmolekyler og fremgangsmåder til at fremstille og anvende samme
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
AU2012351347B2 (en) 2011-12-12 2016-05-19 Baylor College Of Medicine Process of expanding T cells
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2812431B1 (en) 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
KR20150145260A (ko) 2013-04-19 2015-12-29 싸이튠 파마 감소된 혈관 누출 증후근에 대한 사이토카인 유도체 치료
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
CN106659775B (zh) 2014-06-30 2021-08-06 阿尔托生物科学有限公司 基于il-15的分子及其方法和用途
EP4290238A3 (en) 2015-09-18 2024-09-11 Baylor College of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
MX2019004681A (es) 2016-10-21 2019-10-07 Altor Bioscience Corp Moleculas basadas en il-15 multimericas.
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
EP4317422A3 (en) 2017-04-13 2024-05-01 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN111093688A (zh) 2017-05-15 2020-05-01 尼克塔治疗公司 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法
KR102008429B1 (ko) * 2017-06-30 2019-08-07 아주대학교산학협력단 인터루킨-15/인터루킨-15 수용체 알파-Fc 복합체를 포함하는 염증질환 치료 또는 예방용 조성물
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN113164518A (zh) 2018-10-17 2021-07-23 森迪生物科学公司 组合癌症免疫疗法
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
US20220195396A1 (en) * 2020-12-03 2022-06-23 Century Therapeutics, Inc. Genetically Engineered Cells and Uses Thereof
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b

Also Published As

Publication number Publication date
ES2151927T3 (es) 2001-01-16
NZ266264A (en) 1997-01-29
EP0772624A4 (en) 1997-07-02
OA10375A (en) 2001-11-16
GR3035019T3 (en) 2001-03-30
CA2186747A1 (en) 1995-10-19
DE69425906T2 (de) 2001-03-29
DE69425906D1 (en) 2000-10-19
EP0772624B1 (en) 2000-09-13
CA2186747C (en) 2009-01-27
EP0772624A1 (en) 1997-05-14
WO1995027722A1 (en) 1995-10-19
PT772624E (pt) 2001-03-30
ATE196315T1 (de) 2000-09-15

Similar Documents

Publication Publication Date Title
ATE196315T1 (de) Interleukin-15
NO975437L (no) Nytt CD40L-mutein
ATE184052T1 (de) Gdf-1 und uog1 proteine
MX9800719A (es) Proteinas de transporte y sus usos.
DK0669929T3 (da) Elk-ligand, et cytokin
DE69725587D1 (de) Verwendung von wnt polypeptiden
ATE335078T1 (de) Überexpression von säugetier- und virusproteinen
DE69738586D1 (de) Hohe expressionsrate von proteinen
MX9503362A (es) Nuevos anticuerpos br96 mutantes y equivalentes funcionales que reaccionan con carcinomas humanos.
NO854460L (no) Syntetisk hepatitis-b-vaksine inbefattende baade t-celle og b-celledeterminanter.
MX9708426A (es) Polipeptido hk2 de variante estable.
AU4401689A (en) Recombinant dna coding for bacillus thuringiensis endotoxin
DE59410132D1 (de) Humanes zirkulierendes cytokin cc-1
MX9702341A (es) Citoquina designada lerk-6.
GB9826143D0 (en) Tumour rejection antigens
AU656353B2 (en) New variants derived from interferons of type I, production process thereof and their applications
SE9401380D0 (sv) Ny celltillväxt-relaterad peptid och användning därav
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
NO974713D0 (no) Gener som koder for lymfocyttinterferon-regulatorisk faktor (LSIRF) polypeptider
AU7378087A (en) Interleukin-2 induced antineoplastic peptide
DE59009060D1 (de) Überexpression von Proteinen in rekombinanten Wirtszellen.
AU1305097A (en) Protein induced by deprenyl$m(3)
ATE93893T1 (de) Expressionssysteme zur ueberproduktion gewuenschter proteine.